PharmaMar is experiencing an impressive revaluation of its price. During the year, the pharmaceutical company of Marché Continu manages to record an increase of 67%largely thanks to momentum this week following results from the company’s new anti-tumor treatment. The company is currently listed on levels it has not had since June 2022above the 68 euros. The news regarding this drug has led several analysts to improve the valuation of the company, which has increased by 48% the target price of this company’s shares.
Eight analyst houses that track the pharmaceutical company’s performance on the stock market revised their valuation of the company last week, although only three of these companies have changed their expectations regarding their estimated price on the stock market. The analyst who made the largest increase in PharmaMar’s price target is JB Capital expert Joaquín García.
JB Capital had maintained throughout the year the valuation of this company’s share at around 50 euros, which gradually rose to 58 euros during the year and which it finally reached during its September review, accompanied by a sign purchase. But after The publication of the results caused the share price of the pharmaceutical company to suddenly rise by 79%.. The firm estimates PharmaMar’s price target at 102 euros, which represents an upward trend of 50% in the coming months.
The good results
On the other hand, from Bankinter the value of the company’s share increased to 80 eurosa change of 42% compared to the 56 euros at which they previously valued the title. With this new price, they expect an additional increase of 17% on the stock market in the coming months. The bank’s expert, Pedro Echeguren, assures that the main motivation is the “Positive and statistically significant overall survival and progression-free survival results from the clinical study with the combination of Zepzelca and Tecentriq for the treatment of small cell lung cancer“. In this latest analysis of the product, its effectiveness in the treatment of this cancer has been demonstrated.
Echeguren reiterates that this “news is very positive, because it significantly improves the prospects for final approval of Zepzelca as first-line treatmentwhich would imply a considerable increase in revenues from this drug.” The analyst explains that “PharmaMar’s partner, Jazz Pharmaceutical, plans to present to the FDA (US Food and Drug Administration) and PharmaMar to the EMA (European Agency for drugs) , the application for registration of the Zepzelca and Tecentriq combo in the first half of 2025“, which should significantly increase the company’s profits.
Although, at present, this drug has already been approved in 16 territories around the world, pFor the analyst, the boost will be given until 2025, which made him even more positive in his estimates for the company, notably improving his “sales growth forecast for the period between 2023 and 2028 “. up to 13% compared to the previous 10%due to the better expectations that Zepzelca offers”.
On the other hand, from RX Securities also They raise their price target for the pharmaceutical laboratory to 80 euros, which represents an increase of 23% compared to the 65 euros at which they previously valued the shares of this company.
